Episode 55: Alnylam

From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine.

We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine.

This is the story of persistence, platform biology, and the rise of RNA therapeutics.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, a storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

There are moments in biotech where an idea sounds so ambitious, so biologically impossible, that most of the industry dismisses it outright. Monoclonal antibodies were one of those ideas. CRISPR was another. And then there was RNA interference. The concept sounded almost absurd: what if you could selectively silence a disease-causing gene before the harmful protein was ever made? Not block the protein. Not inhibit the pathway. Not manage symptoms. Just stop the genetic message itself.

For decades, scientists called RNA interference—or RNAi—one of the most powerful biological discoveries ever made. But there was a problem. No one knew how to turn it into a drug. RNA molecules are fragile. They degrade instantly in blood. They trigger immune reactions. They struggle to enter cells. And even if they make it into the body, getting them to the right tissue is extraordinarily difficult.

Most people thought the field would collapse under its own complexity. But one company refused to let go of the idea. That company was Alnylam Pharmaceuticals.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Discovery That Changed Biology: RNA Interference

To understand Alnylam, we first need to understand RNA interference itself. The story begins in 1998 with Andrew Fire and Craig Mello.

Working in C. elegans worms, they discovered that double-stranded RNA could selectively shut down specific genes. This wasn’t just gene regulation. This was biological code suppression.

Cells already had a built-in mechanism for silencing genetic instructions.

The process works like this:

Messenger RNA—or mRNA—is the blueprint cells use to make proteins. RNAi introduces small interfering RNAs, called siRNAs, which bind to complementary mRNA molecules and mark them for destruction.

No mRNA means no protein. And no protein means you can potentially stop disease at its source.

The discovery was so important that Fire and Mello received the Nobel Prize in 2006. But in the early 2000s, RNAi was viewed more as a scientific curiosity than a viable therapeutic platform.

That’s where Alnylam enters the story.

Founding Story: Betting Everything on Impossible Biology

Alnylam Pharmaceuticals was founded in 2002 in Cambridge, Massachusetts.

And from the very beginning, the company was essentially a moonshot.

The founding scientific architects included:

• Phillip Sharp of Massachusetts Institute of Technology
• David Bartel
• Thomas Tuschl
• Paul Schimmel

This was essentially an all-star team of RNA biology.

But the company faced an enormous problem:

RNAi worked beautifully in petri dishes.

It failed almost everywhere else.

RNA molecules degraded rapidly in the bloodstream. They couldn’t cross cell membranes efficiently. They activated innate immune pathways. And nobody knew how to deliver them safely to target tissues.

At the time, many investors considered RNA therapeutics fundamentally unworkable.

But Alnylam believed the core issue wasn’t the biology. It was delivery. And that insight would define the company for the next two decades.

If antibodies defined the 1990s, delivery systems defined the 2000s. Because in biotech, the molecule is only half the story.

The real question is: Can you get it where it needs to go?

For Alnylam, this became an obsession. The company spent years engineering lipid nanoparticles—tiny delivery vehicles capable of protecting RNA molecules and transporting them into cells.

This culminated in one of the most important partnerships in company history: A collaboration with Tekmira Pharmaceuticals, later renamed Arbutus Biopharma. Together, they advanced lipid nanoparticle technology that could finally stabilize siRNA molecules in circulation.

But the field still faced skepticism. Large pharma companies entered RNAi… then exited.

Some called it overhyped. Others called it unscalable. And by the late 2000s, the industry was beginning to lose patience.

Alnylam Pharmaceuticals (ALNY) priced its initial public offering (IPO) on May 27, 2004, at $6.00 per share. The stock began trading on the NASDAQ National Market on May 28, 2004. The offering consisted of 5 million shares, raising roughly $30 million in proceeds.

Rise to Fame: The GalNAc Revolution

Then came the breakthrough that changed everything. GalNAc. Specifically: N-acetylgalactosamine conjugate delivery.

This became the defining technological innovation in Alnylam’s history.

Scientists discovered that GalNAc molecules bind naturally to ASGPR receptors on liver cells—hepatocytes.

Which meant something revolutionary: You could chemically attach siRNA molecules to GalNAc and selectively deliver them to the liver with remarkable precision.

No complicated nanoparticles. No massive infusion systems. No extreme toxicity.

Suddenly, RNAi therapeutics became practical.

And the liver became the perfect target organ.

This was the moment Alnylam transformed from a struggling RNA company into a true platform biotech.

Because once delivery worked, the pipeline exploded.

The First Approved Drug: Onpattro

In 2018, Alnylam achieved a historic milestone.

The FDA approved: Onpattro

The first-ever RNA interference therapeutic approved anywhere in the world.

The indication was hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis—a devastating disease caused by misfolded transthyretin protein accumulating in nerves and organs.

Onpattro works by silencing the TTR gene in the liver.

No TTR production means reduced toxic protein accumulation.

This was historic not just for Alnylam—but for the entire RNA field.

Because RNAi had finally crossed the line from concept to medicine.

The Big Three: Alnylam’s Core Products

Onpattro — The Pioneer

Onpattro proved RNAi could work clinically.

But it also revealed limitations:

• Intravenous infusion
• Premedication requirements
• Complex administration

It was revolutionary scientifically—but operationally cumbersome.

Still, it opened the floodgates.

Givlaari — Silencing Rare Metabolic Disease

Next came: Givlaari

Approved for acute hepatic porphyria.

This disease causes severe neurological attacks due to toxic buildup of heme pathway intermediates.

Alnylam targeted ALAS1 in the liver, dramatically reducing toxic metabolite production.

This showcased a key RNAi advantage:

You don’t need to replace proteins.
 You can selectively suppress pathological pathways upstream.

Amvuttra — The Platform Matures

Then came:
 Amvuttra

This was the “second-generation” evolution of Onpattro.

Amvuttra (vutrisiran) targets and degrades transthyretin (TTR) messenger RNA (mRNA) in the liver to reduce the production of both wild-type and mutant TTR protein. By silencing this mRNA, it lowers serum TTR levels to treat polyneuropathy and cardiomyopathy associated with hereditary (hATTR) and wild-type (wtATTR) amyloidosis.

Same disease target.
 Better delivery platform.

Subcutaneous injection.
 Improved convenience.
 Longer durability.

This represented Alnylam’s transition from “scientific pioneer” to commercial biotech operator.

Partnerships: Big Pharma Finally Believes

For years, RNAi struggled for legitimacy.

Now, everyone wanted in.

Alnylam signed major collaborations with:

• Novartis
• Sanofi
• Regeneron Pharmaceuticals
• Roche

Early partnerships with Novartis helped legitimize RNAi during a period of heavy skepticism and provided critical funding for delivery technology development. Its landmark collaboration with Sanofi, particularly through Genzyme, accelerated the development and commercialization of Onpattro and later Amvuttra, culminating in the first FDA-approved RNAi therapy in history. The partnership with Regeneron Pharmaceuticals expanded RNAi into broader cardiometabolic and chronic disease markets, while the alliance with Roche pushed the platform into neurology and CNS delivery. Together, these collaborations demonstrated that Alnylam had not simply created a drug pipeline—it had built a programmable gene-silencing engine capable of targeting multiple diseases across medicine.

The industry finally recognized what Alnylam had built:

Not a single drug.

A programmable silencing platform.

The Setbacks: Patisiran, Revusiran, and Investor Doubt

But the road was not smooth.

One of Alnylam’s darkest moments came with: Revusiran.

A Phase 3 RNAi therapy targeting transthyretin amyloidosis.

The trial was halted in 2016 after increased mortality signals emerged.

This was devastating.

The stock collapsed.
 The field panicked.
 Critics questioned whether RNAi itself was unsafe.

But Alnylam did something critical:

They pivoted quickly.

They improved chemistry.
 Improved delivery.
 Improved dosing.

And instead of collapsing, the company emerged stronger.

That resilience became one of the defining themes of the Alnylam story.

People Who Made Their Mark

John Maraganore

The longtime CEO who shepherded Alnylam through skepticism, platform crises, and eventual validation.

John Maraganore is one of the most influential executives in the history of RNA therapeutics and is widely credited with transforming Alnylam Pharmaceuticals from a speculative platform biotech into a commercially validated RNAi powerhouse.

Trained as a molecular biologist, Maraganore earned his PhD in biochemistry and molecular biology from the University of Chicago and later worked in antisense and nucleic acid therapeutics before joining Alnylam in 2002, shortly after the company’s founding.

He became CEO in 2003 and led the company for nearly two decades during one of the most difficult technological journeys in biotech. Under his leadership, Alnylam survived repeated industry skepticism surrounding RNA interference, solved major delivery challenges, built strategic partnerships with companies like Novartis and Sanofi, and ultimately achieved the first FDA approval of an RNAi therapeutic with Onpattro in 2018.

Maraganore became known for his long-term platform-building mindset. Rather than focusing on a single drug, he positioned Alnylam as a “genetic medicine company,” emphasizing repeatable delivery systems, liver-targeting chemistry, and scalable RNAi infrastructure.

By the time he stepped down as CEO in 2021, Alnylam had evolved from a high-risk experimental biotech into one of the defining companies of the RNA medicine era.

Lessons from Alnylam

1. Delivery is everything

In biotech, breakthroughs often come from delivery systems—not just targets.

2. Platforms outlast products

RNAi succeeded because Alnylam built infrastructure, chemistry, and repeatability.

3. Scientific timing matters

Alnylam was early enough to pioneer—but patient enough to survive.

4. Rare diseases are strategic launchpads

Rare disease allowed the company to validate RNAi before expanding into massive indications.

What’s Next: The RNAi Expansion Era

As of 2026, Alnylam sits at the center of the RNA therapeutics revolution. As of May 13, 2026, Alnylam Pharmaceuticals (ALNY) has a market capitalization of approximately $40 billion, with a stock price trading at $291. The company has experienced significant growth following positive data for its ATTR-CM drug, vutrisiran, and strong Q1 2026 earnings that beat estimates. Alnylam Pharmaceuticals has approximately 2,500 to 2,770 employees worldwide. Headquartered in Cambridge, Massachusetts, the company has a global presence with operations in over 16 countries and more than 25 offices across North America, Europe, Asia, and South America.

The company is pushing into:

• Cardiometabolic disease
• CNS delivery
• Combination RNA therapies
• Earlier intervention strategies

And increasingly, RNAi is converging with:

• CRISPR
• Gene editing
• Personalized medicine
• AI-driven target discovery

The broader vision is becoming clear:

Medicine is shifting from blocking proteins… to programming gene expression itself.

Today, Alnylam is moving beyond ultra-rare disorders.

The company is now targeting:

• Hypertension
• Cardiovascular disease
• Metabolic disease

This shift matters enormously.

Rare disease validates platforms. Common disease scales them.

And if RNAi enters mainstream cardiovascular medicine successfully, the commercial ceiling becomes enormous.

That’s not just a drug innovation.

That’s a healthcare system disruption.

Outro: The Silence That Changed Medicine

Alnylam’s story is ultimately about persistence.

For years, RNAi looked impossible.
 Too unstable.
 Too fragile.
 Too complex.

But the company stayed focused on the engineering problem.

And eventually, they solved it.

Today, RNA interference is no longer a scientific curiosity.

It’s an industry.

And Alnylam—the company once dismissed as overly ambitious—became the blueprint for how programmable medicine might actually work.

This has been Petri Dish Perspectives: Biotech Unleashed. I’m Manead.

And next time, we’ll dive into another company rewriting the rules of biology.

Until then—stay curious.

References

1. www.wikipedia.org
2. https://www.fiercepharma.com/ 
3. https://endpoints.news/ 
4. https://www.alnylam.com/